| Size | Price | Stock | Qty |
|---|---|---|---|
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| Other Sizes |
Purity: ≥98%
| Targets |
Meprednisone targets the glucocorticoid receptor. It acts as a glucocorticoid receptor agonist. It modulates the glucocorticoid receptor. By activating the glucocorticoid receptor, it modulates gene expression, leading to anti-inflammatory and immunosuppressant effects. It blocks the action of glucocorticoids. It is a methylated derivative of prednisone.
|
|---|---|
| ln Vitro |
In vitro, Meprednisone acts as a glucocorticoid receptor agonist. It modulates the glucocorticoid receptor. Its activity has been characterized in cell-based assays measuring its effects on glucocorticoid-responsive gene expression. These in vitro studies confirm its mechanism as a glucocorticoid receptor agonist. It is used in research to study inflammatory and autoimmune disease mechanisms.
|
| ln Vivo |
In vivo, Meprednisone is an orally active glucocorticoid. It is used in the exploration of inflammatory and autoimmune disease mechanisms. Its effects are mediated through the glucocorticoid receptor. It has anti-inflammatory and immunosuppressant properties. However, specific detailed in vivo study results are not extensively documented in standard summaries. It is a research compound.
|
| Enzyme Assay |
Non-cellular receptor binding assays for Meprednisone typically involve measuring its affinity for the glucocorticoid receptor. These assays use purified receptor or cytosolic preparations and measure the displacement of a labeled ligand. Its binding affinity and potency as a glucocorticoid receptor agonist can be characterized. These experiments are essential for characterizing its receptor binding properties.
|
| Cell Assay |
In vitro cell-based assays for Meprednisone are conducted using cells expressing the glucocorticoid receptor to assess its effects on gene expression. Cells are treated with the compound, and the expression of glucocorticoid-responsive genes is measured by qPCR or reporter gene assays. Its effects on inflammatory cytokine production can also be assessed. These experiments are crucial for confirming its mechanism of action.
|
| Animal Protocol |
In vivo animal studies for Meprednisone are typically conducted in animal models of inflammation or autoimmune disease to evaluate its efficacy. The compound is administered orally, and its effects on disease severity and inflammatory markers are assessed. However, specific detailed protocols are not extensively documented in standard summaries. It is used in research to study inflammatory and autoimmune disease mechanisms.
|
| ADME/Pharmacokinetics |
Meprednisone has a molecular weight of 372.46 g/mol. It is an orally active compound. As a research compound, its pharmacokinetic properties are not extensively documented. It is expected to be absorbed after oral administration and to be metabolized in the liver. Its half-life and other pharmacokinetic parameters are not detailed in standard summaries.
|
| Toxicity/Toxicokinetics |
Comprehensive toxicological data for Meprednisone are limited, as it is a research compound. It is intended for laboratory use only and is not for human consumption. As with all research chemicals, appropriate safety precautions should be taken when handling Meprednisone. Its safety profile in vivo has not been extensively characterized.
|
| References |
Am J Contact Dermat.2003 Dec;14(4):179-87.
|
| Additional Infomation |
Meprednisone is a 21-hydroxysteroid.
Meprednisone (Betapar) is a glucocorticoid and a methylated derivative of prednisone. It acts as a glucocorticoid receptor agonist. It is an orally active compound used in research to study inflammatory and autoimmune disease mechanisms. Meprednisone is not an approved drug and is available as a research compound. |
| Molecular Formula |
C22H28O5
|
|
|---|---|---|
| Molecular Weight |
372.45
|
|
| Exact Mass |
372.193
|
|
| CAS # |
1247-42-3
|
|
| Related CAS # |
|
|
| PubChem CID |
5284587
|
|
| Appearance |
White to off-white solid powder
|
|
| Density |
1.3±0.1 g/cm3
|
|
| Boiling Point |
574.4±50.0 °C at 760 mmHg
|
|
| Melting Point |
204-206ºC
|
|
| Flash Point |
315.2±26.6 °C
|
|
| Vapour Pressure |
0.0±3.6 mmHg at 25°C
|
|
| Index of Refraction |
1.595
|
|
| LogP |
2.06
|
|
| Hydrogen Bond Donor Count |
2
|
|
| Hydrogen Bond Acceptor Count |
5
|
|
| Rotatable Bond Count |
2
|
|
| Heavy Atom Count |
27
|
|
| Complexity |
795
|
|
| Defined Atom Stereocenter Count |
7
|
|
| SMILES |
C[C@@]1(C2)[C@](C(CO)=O)(O)[C@@H](C)C[C@@]1([H])[C@]3([H])CCC4=CC(C=C[C@]4(C)[C@@]3([H])C2=O)=O
|
|
| InChi Key |
PIDANAQULIKBQS-RNUIGHNZSA-N
|
|
| InChi Code |
InChI=1S/C22H28O5/c1-12-8-16-15-5-4-13-9-14(24)6-7-20(13,2)19(15)17(25)10-21(16,3)22(12,27)18(26)11-23/h6-7,9,12,15-16,19,23,27H,4-5,8,10-11H2,1-3H3/t12-,15-,16-,19+,20-,21-,22-/m0/s1
|
|
| Chemical Name |
(8S,9S,10R,13S,14S,16S,17R)-17-hydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-7,8,9,10,12,13,14,15,16,17-decahydro-3H-cyclopenta[a]phenanthrene-3,11(6H)-dione
|
|
| Synonyms |
|
|
| HS Tariff Code |
2934.99.9001
|
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
|
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
|
|||
|---|---|---|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 3 mg/mL (8.05 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 30.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 3 mg/mL (8.05 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 30.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 3 mg/mL (8.05 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.6849 mL | 13.4246 mL | 26.8492 mL | |
| 5 mM | 0.5370 mL | 2.6849 mL | 5.3698 mL | |
| 10 mM | 0.2685 mL | 1.3425 mL | 2.6849 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA